Holen Sie sich die Stockscreener-App
15.60
0.26%
0.024
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt TNDM?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$15.58
Offen:
$15.48
24-Stunden-Volumen:
363.51K
Relative Volume:
0.23
Marktkapitalisierung:
$1.04B
Einnahmen:
$796.00M
Nettoeinkommen (Verlust:
$-136.49M
KGV:
-7.466
EPS:
-2.09
Netto-Cashflow:
$-64.24M
1W Leistung:
-1.70%
1M Leistung:
-9.40%
6M Leistung:
-57.85%
1J Leistung:
-55.64%
1-Tages-Spanne:
$15.05
$15.66
1-Wochen-Bereich:
$15.05
$17.19
52-Wochen-Spanne:
$14.31
$47.60
Tandem Diabetes Care Inc Stock (TNDM) Company Profile
Firmenname
Tandem Diabetes Care Inc
Sektor
Branche
Telefon
858-366-6900
Adresse
12400 HIGH BLUFF DRIVE, San Diego, CA
Vergleichen Sie TNDM mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
TNDM
Tandem Diabetes Care Inc
|
15.62 | 1.11B | 796.00M | -136.49M | -64.24M | -2.09 |
|
ABT
Abbott Laboratories
|
127.73 | 223.66B | 43.11B | 13.98B | 6.66B | 7.98 |
|
BSX
Boston Scientific Corp
|
106.13 | 157.95B | 18.49B | 2.51B | 2.72B | 1.68 |
|
SYK
Stryker Corp
|
380.82 | 153.02B | 23.22B | 2.86B | 3.58B | 7.40 |
|
MDT
Medtronic Plc
|
89.60 | 117.42B | 33.54B | 4.66B | 5.19B | 3.62 |
|
EW
Edwards Lifesciences Corp
|
79.67 | 47.61B | 5.69B | 4.15B | 623.10M | 6.95 |
Tandem Diabetes Care Inc Stock (TNDM) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-07-09 | Herabstufung | Citigroup | Neutral → Sell |
| 2025-06-16 | Eingeleitet | Truist | Hold |
| 2025-04-10 | Eingeleitet | Mizuho | Neutral |
| 2025-03-05 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2025-03-04 | Herabstufung | Citigroup | Buy → Neutral |
| 2025-03-03 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2025-02-28 | Herabstufung | Bernstein | Outperform → Mkt Perform |
| 2024-12-02 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2024-11-06 | Eingeleitet | Bernstein | Outperform |
| 2024-10-04 | Eingeleitet | Goldman | Neutral |
| 2024-10-02 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2024-08-22 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2024-08-08 | Eingeleitet | Canaccord Genuity | Buy |
| 2024-05-30 | Eingeleitet | Redburn Atlantic | Buy |
| 2024-05-22 | Hochstufung | Citigroup | Neutral → Buy |
| 2024-04-29 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2024-04-25 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2024-03-26 | Hochstufung | Stifel | Hold → Buy |
| 2023-08-04 | Herabstufung | Citigroup | Buy → Neutral |
| 2023-05-05 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2023-04-24 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2023-03-29 | Eingeleitet | UBS | Neutral |
| 2023-01-26 | Eingeleitet | Wolfe Research | Peer Perform |
| 2022-11-15 | Hochstufung | Wells Fargo | Underweight → Equal Weight |
| 2022-10-18 | Eingeleitet | Barclays | Overweight |
| 2022-10-12 | Eingeleitet | Jefferies | Buy |
| 2022-08-09 | Herabstufung | Wells Fargo | Overweight → Underweight |
| 2022-03-02 | Fortgesetzt | BofA Securities | Neutral |
| 2022-01-19 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2021-07-21 | Fortgesetzt | Cowen | Outperform |
| 2021-05-25 | Eingeleitet | Barclays | Underweight |
| 2020-12-15 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2020-08-20 | Eingeleitet | Wells Fargo | Overweight |
| 2020-07-31 | Hochstufung | Guggenheim | Neutral → Buy |
| 2020-07-06 | Hochstufung | Citigroup | Neutral → Buy |
| 2020-06-18 | Bestätigt | Raymond James | Outperform |
| 2020-04-24 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2020-03-23 | Herabstufung | Guggenheim | Buy → Neutral |
| 2020-03-05 | Eingeleitet | Citigroup | Neutral |
| 2020-02-06 | Eingeleitet | Raymond James | Outperform |
| 2020-02-04 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2019-10-18 | Eingeleitet | Guggenheim | Buy |
| 2019-10-04 | Hochstufung | UBS | Neutral → Buy |
| 2019-05-17 | Bestätigt | BofA/Merrill | Neutral |
| 2019-05-13 | Eingeleitet | SVB Leerink | Outperform |
| 2019-03-08 | Eingeleitet | BMO Capital Markets | Outperform |
| 2019-03-05 | Bestätigt | BofA/Merrill | Neutral |
| 2019-02-27 | Bestätigt | Lake Street | Buy |
| 2018-11-21 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2018-09-26 | Bestätigt | Dougherty & Company | Buy |
| 2018-09-26 | Bestätigt | Piper Jaffray | Overweight |
Alle ansehen
Tandem Diabetes Care Inc Aktie (TNDM) Neueste Nachrichten
Artificial Pancreas market Accelerates with Machine Learning & - openPR.com
Tandem Diabetes Care Announces Upcoming Conference Participation - Business Wire
Tandem Diabetes Care, Inc. (TNDM) Expected to Beat Earnings Estimates: Should You Buy? - Yahoo Finance
Tandem Diabetes Care (NASDAQ:TNDM) Shareholders Are up 15% This Past Week, but Still in the Red Over the Last Five Years - 富途牛牛
Tandem Diabetes Care Inc.’s Price Action Aligns with Quant SignalsReliable Investment Entry Signals Confirmed by Charts - metal.it
Published on: 2025-07-29 20:42:52 - metal.it
Wyckoff Accumulation Phase Possible in Tandem Diabetes Care Inc.AI Driven Buy Alert Trade Blueprint Released - metal.it
Published on: 2025-07-29 04:06:14 - metal.it
Quant Strategy Flags Tandem Diabetes Care Inc. for EntryConsistent Profit Pattern Recognition Tools Shared - metal.it
Tandem Diabetes Care Stock Rebounds as Investors Eye Earnings ReportNews and Statistics - IndexBox
Why Tandem Diabetes (TNDM) Stock Is Trading Up Today - Yahoo Finance
What are analysts’ price targets for Tandem Diabetes Care Inc. in the next 12 monthsMassive portfolio appreciation - jammulinksnews.com
What is the risk reward ratio of investing in Tandem Diabetes Care Inc. stockBuild a portfolio that stands the test of time - jammulinksnews.com
Is it the right time to buy Tandem Diabetes Care Inc. stockDiscover hidden gems in the stock market - jammulinksnews.com
How does Tandem Diabetes Care Inc. compare to its industry peersAdvanced Screener Ideas For Fast Growth - jammulinksnews.com
What institutional investors are buying Tandem Diabetes Care Inc. stockSuperior risk-adjusted returns - jammulinksnews.com
How strong is Tandem Diabetes Care Inc. company’s balance sheetCapitalize on fast-growing stocks today - jammulinksnews.com
Tandem Diabetes Care Inc. Stock Support and Resistance Levels You Should KnowPotential Rocket List - metal.it
What is Tandem Diabetes Care Inc. company’s growth strategyStrong return on assets - jammulinksnews.com
What are the latest earnings results for Tandem Diabetes Care Inc.Invest smarter with daily trading signals - jammulinksnews.com
What are Tandem Diabetes Care Inc. company’s key revenue driversInvest smarter with real-time trading signals - jammulinksnews.com
Why Tandem Diabetes Care Inc. stock attracts strong analyst attentionSafer Investing With Bigger Upside - metal.it
What makes Tandem Diabetes Care Inc. stock price move sharplyFree Stock Market Insider Analysis - metal.it
What analysts say about Tandem Diabetes Care Inc. stockExplosive trading growth - Autocar Professional
Is Tandem Diabetes Care Inc. a good long term investmentUnprecedented market success - Autocar Professional
Tandem Diabetes Care Inc. Stock Analysis and ForecastFree Predictions - Autocar Professional
Marriott Vacations, Wabash, SmartRent, Vestis, and Tandem Diabetes Stocks Trade Up, What You Need To Know - Yahoo Finance
Insulin Pumps Market Outlook Report 2025, with Leading Player Profiles for Medtronic, Insulet, Tandem Diabetes Care, and More - Yahoo Finance
What drives Tandem Diabetes Care Inc. stock priceSuperior stock growth - jammulinksnews.com
Insulin Pump Market Booming with AI Integration, Attracts Focus - openPR.com
Down 27.0% in 4 Weeks, Here's Why You Should You Buy the Dip in Tandem Diabetes Care (TNDM) - Yahoo Finance
Wearable Injectors Market is expected to reach USD 24.99 billion - openPR.com
Digital Diabetes Management Market is projected to reach US$ - openPR.com
Diabetes Devices Market is projected to grow to US$ 64.8 billion - openPR.com
Finanzdaten der Tandem Diabetes Care Inc-Aktie (TNDM)
Umsatz
Nettogewinn
Free Cashflow
ENV
Tandem Diabetes Care Inc-Aktie (TNDM) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Carpenter Rick | Chief Technology Officer |
Jun 16 '25 |
Option Exercise |
0.00 |
406 |
0 |
21,426 |
| Novara Mark David | EVP & CHIEF COMMERCIAL OFFICER |
Jun 16 '25 |
Option Exercise |
0.00 |
7,414 |
0 |
32,609 |
| Cha Myoungil | Director |
Jun 16 '25 |
Option Exercise |
0.00 |
1,749 |
0 |
13,699 |
| Malagueira Joao Paulo Falcao | Director |
Jun 16 '25 |
Option Exercise |
0.00 |
1,749 |
0 |
13,699 |
| Sodhi Rajwant | Director |
May 22 '25 |
Option Exercise |
20.64 |
4,387 |
90,548 |
15,521 |
| McGroddy-Goetz Kathleen | Director |
May 22 '25 |
Option Exercise |
20.64 |
4,387 |
90,548 |
17,853 |
| Cha Myoungil | Director |
May 22 '25 |
Option Exercise |
20.64 |
4,387 |
90,548 |
11,950 |
| ROBERTSON REBECCA B | Director |
May 22 '25 |
Option Exercise |
20.64 |
4,387 |
90,548 |
13,783 |
| Howell Peyton R | Director |
May 22 '25 |
Option Exercise |
20.64 |
4,387 |
90,548 |
21,077 |
| TWOMEY CHRISTOPHER J | Director |
May 22 '25 |
Option Exercise |
20.64 |
4,387 |
90,548 |
15,675 |
0.78%
0.51%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):